myriad® | WOMEN'S HEALTH

PORTFOLIO OF PRODUCTS



WITH YOU EVERY STEP OF THE WAY

OVERVIEW

MYRIAD WOMEN'S HEALTH GENETIC PRODUCTS



Myriad Women's Health

Myriad Women's Health is your premier genetic testing partner when you need a result with actionable guidance to deliver superior patient care, which empowers women and their families to make critical and timely healthcare decisions.

We are dedicated to providing you:

Proven test performance for confident decision-making
Our next generation sequencing platforms are scientifically validated to provide industry-leading sensitivities and specificities. This ensures you can provide the best care for your patients based on their results.

Support at every step so you can focus on patient care
From pre-test education to post-test support, we partner with you to integrate genetic testing seamlessly into your clinic's existing workflow so that you can spend more time with your patients.

Comprehensive patient assistance to expand access and affordability
We are committed to making genetic testing accessible for all patients who can benefit so that they can make informed choices about their health, their families, and their futures, regardless of their financial situation.

2M +
patient results delivered

60 +
peer-reviewed publications*

100,000 +
counseling sessions performed

250M +
lives in-network

Our Genetic Products

Myriad myRisk®
Hereditary Cancer
Help patients get ahead of cancer with our hereditary cancer test.

- For men and women
- 10mL blood or saliva sample
- Results in ~2 weeks

Foresight®
Carrier Screen
Unmatched detection of at-risk couples for serious heritable conditions.

- For all individuals who are pregnant or planning a pregnancy
- 4mL blood or saliva sample
- Results in ~2 weeks

Prequel™
Prenatal Screen
Reliable results, the first time with our noninvasive prenatal screen.

- For pregnant women
- 10mL blood sample
- Results in ~1 week

*Total for all Myriad Women's Health products

Myriad Complete™

We make genetic screening and testing simple for your patients, and for your practice.

Myriad Complete is a proprietary suite of services, designed to allow seamless integration of genetic screening and testing in your practice. These workflow solutions support patients and healthcare providers through the patient's journey from pre-test education to post-test educational consults.

EDUCATION

We provide resources to help you educate your patients about Myriad products.

- Patient education resources
- Electronic patient identification tools

ACCESS

We offer a comprehensive program to make our products accessible and affordable for more of your patients.

- Remote testing options
- Personalized cost estimates and financial assistance programs
- Mobile phlebotomy

RESULTS

We deliver screening and testing results effectively and thoroughly so you can focus on care plans.

- Online ordering and results management
- Patient portal

CONSULTS

We provide consults from patient educators, who are genetic counselors, tailored to help answer any questions your patients may have.

- Post-test patient consults
- Detailed consult notes for providers
- Provider access to genetic counselors

YOUR PARTNER IN PATIENT CARE. MYRIAD COMPLETE.

Myriad myRisk® Hereditary Cancer

Enhanced with riskScore®

Myriad myRisk with riskScore blends analysis of genetic risk factors with clinical and cancer family history to deliver the most comprehensive, clinically actionable results to help providers manage and reduce their patients' risk of cancer.

Multigene panel determines hereditary cancer risk associated with 8 cancer sites:

- Breast
- Colorectal
- Melanoma
- Gastric
- Ovarian
- Endometrial
- Pancreatic
- Prostate

riskScore Breast Cancer Prediction Tool*

Clinically validated[1-5] to predict a woman's 5-year and remaining lifetime risk of developing breast cancer using genetic markers and clinical risk factors:

- More than 80 well-studied genetic markers linked to breast cancer risk
- Tyrer-Cuzick risk factors
- Mutation status in certain genes, such as *CHEK2*

myRisk Management Tool (MMT)

Test results are accompanied with the MMT which summarizes current professional society guidelines for medical management based on patients' individual results.

54% of results in the OBGYN and Primary Care setting identify that a medical management change for the patient may be warranted.[18]

Why cancer risk assessment and testing

There is extensive support among leading medical organizations for the utilization of cancer risk assessment and testing due to the high prevalence of at-risk patients and proven success of medical interventions to improve patient outcomes.

1 in 4 patients Approximately 1 in 4 patients in the community OBGYN setting are appropriate for hereditary cancer testing.[6]

90% of high-risk women are not tested for *BRCA1/BRCA2*[6-7]

Interventions are proven to reduce risk[8-11]

ACOG, USPSTF & NCCN support hereditary cancer risk assessment as the standard of care[12-14]

Myriad is your trusted advisor

- **Analytically validated high-throughput laboratory with >99.92% sensitivity and >99.99% specificity**
- **Industry leading, FDA-reviewed[16] variant interpretation program with powerful methods unique to Myriad**
  - Definitive results for 43-63% of VUS (variants of uncertain significance) classifications by other labs[20]
- **Lifetime commitment to patients & providers**
  - In a study of over 1.6 million patients who underwent testing between 2006 & 2016, Myriad provided more than 60,000 results with definitive classifications for previously unknown VUSs, providing clarity for patients and providers[17]

27+

years of experience in hereditary cancer testing

Clinical support at every step

We provide useful tools and resources at every step so you can better integrate cancer risk assessment and testing into your practice.

Patient identification
Customizable screening tools designed to optimize identification of appropriate patients.

Pre-test education
We provide you with the resources you need to effectively educate your patients on the benefits and impact of testing.

Results and next steps
No matter your patients' results, we provide clear and actionable information so you can confidently manage your patients' future cancer risk.

KNOW THEIR RISK. PROTECT THEIR FUTURE. MYRIAD MYRISK.

*Based on research at the time of product launch, riskScore is only calculated from women of solely European ancestry under the age of 85 and without a personal history of breast cancer, LCIS, hyperplasia, or a breast biopsy of unknown results. A riskScore result is not calculated if the patient is known to carry a mutation in a breast cancer risk gene other than CHEK2.

Myriad Foresight® Carrier Screen

The Myriad Foresight Carrier Screen maximizes detection of at-risk couples for serious, clinically-actionable, and prevalent conditions.

The Foresight Carrier Screen can be offered to all individuals and couples who are pregnant or planning to become pregnant. Panels can be customized, but most providers order one of the following:

Fundamental panel*

Basic carrier screen

- Cystic fibrosis
- Spinal muscular atrophy

Fundamental plus panel*

Guidelines-focused carrier screen

- 14 genes
- Includes common conditions recognized in guidelines

Universal panel*

Expanded carrier screen

- Up to 176 genes
- Includes conditions that could:
  - Improve outcomes with early intervention
  - Lead to shortened life expectancy
  - Cause intellectual disability
  - Have limited or no treatment options

**Fragile X (for females)*

Optimize outcomes with carrier screening

Carrier screening can provide early insights to enhance your care plan and allow individuals and couples to make informed family planning decisions. Myriad Women's Health pioneered expanded carrier screening (ECS) to help optimize health outcomes for your patients and their families.

Many patients may have an elevated reproductive risk

Serious inherited conditions

1 in 300 pregnancies are affected by a serious condition screened by the Myriad Foresight Carrier Screen[1]

Down syndrome

1 in 800 births affected by Down syndrome[2]

When individuals and couples have information, they use it!

77% of at-risk couples screened prepregnancy pursued alternative reproductive options

37% of couples screened prenatally pursued or planned for prenatal diagnosis[3]

UTMOST CONFIDENCE IN EVERY RESULT.

MYRIAD FORESIGHT.

Equity in Care Across Ethnicities

77% OF CARRIERS WERE MISSED WHEN FOLLOWING SELF-REPORTED ETHNICITY GUIDELINES[4]

Foresight maximizes detection rates across ethnicities, allowing you to establish a consistent protocol to deliver equity in care to all patients, regardless of background.

Prioritizing clinical significance in panel design

Our panel design is based on four strict criteria to ensure you and your patients receive meaningful and clinically actionable information.[5*]

SEVERITY | ACTIONABILITY | PREVALENCE | SENSITIVITY

**See myriadwomenshealth.com/diseases for a complete list of genes on the Foresight Carrier Screen*

Highest published at-risk couple detection for serious conditions

Foresight enables providers to achieve the true purpose of carrier screening: identify couples at-risk for serious and actionable conditions.



1 in 22

couples are identified as at-risk by the Foresight Carrier Screen[1]

Advanced technology increases detection rates

A validated assay[1] that uses full-exon sequencing, panel-wide deletion calling, and real-time curation to produce >99% detection rates across ethnicities for most conditions, enabling you to trust both positive and negative results.



>99%

Detection rates for the vast majority of conditions on the panel

○ **Full-exon sequencing with deletion calling**
looks at the entire exon to identify all disease-causing mutations

◇ **Targeted sequencing**
focuses only on specific areas of the exon where mutations are associated with a disease

Myriad Prequel™ Prenatal Screen

with AMPLIFY™ Technology

The Myriad Prequel Prenatal Screen is a noninvasive prenatal screen (NIPS) that uses whole genome sequencing (WGS) and combines custom algorithms and bioinformatics with individualized expert analysis to provide your patients reliable results, the first time[1].

Conditions covered include:

Common aneuploidies

- Trisomy 13 *(Patau syndrome)*
- Trisomy 18 *(Edwards syndrome)*
- Trisomy 21*(Down syndrome)*

Expanded Aneuploidies Analysis

- *Analyzes all 22 numbered chromosome pairs to provide additional genetic insights into the health of the pregnancy.*

Sex chromosome analysis*

- Monosomy X *(Turner syndrome)*
- Klinefelter syndrome *(XXY)*
- Trisomy X syndrome *(XXX)*
- XYY syndrome *(Jacobs syndrome)*
- Male *(XY)*
- Female *(XX)*

Microdeletions*

- 1p36 deletion syndrome
- 4p deletion *(Wolf-Hirschhorn syndrome)*
- 5p deletion*(Cri-du-Chat syndrome)*
- 15q11 deletion *(Angelman or Prader-Willi syndrome)*
- 22q11.2 deletion *(DiGeorge syndrome)*

Why noninvasive prenatal screening (NIPS)

✓ **100x lower false positives**
The false positive rate of NIPS is 100x lower than serum screening in patients in the general obstetric population.[1]

✓ **20x better positive predictive value**
Positive predictive value (PPV) is 20-fold higher than in standard serum screening.[1]

✓ **Recognized by medical societies**
ACOG and SMFM recommend noninvasive prenatal screening as the most sensitive and specific screen for all women[3].

One test for all your patients

Guidelines support screening for all women for common autosomal aneuploidies[4,5,6] .Prequel is effective in all pregnancy types, including:

Patients with low fetal fraction (ex high BMI, early gestational age)[7]

Pregnancies from ovum donors, surrogates, consanguineous couples

Patients pregnant with twins

*Microdeletion, expanded aneuploidy anaylsis, and sex chromosome screening are optional. When analyzing sex chromosomes, we can report the predicted fetal sex. Microdeletion, sex chromosome aneuploidy, and expanded aneuploidy analysis can be performed only in singleton pregnancies. Sex chromosome analysis in twins is limited to predicting the individual twin fetal sexes

Reliable results the first time

Prequel's industry-leading test failure rate of 0.1%[1,6] results in **fewer redraws, decreased anxiety for your patients, and fewer invasive procedures that can lead to fetal risk.**

0.1%

Test failure rate

Prequel with AMPLIFY technology enriches fetal fractions leaving virtually no sample with a fetal fraction <4%[6].

With Prequel, you don't need a fetal fraction cutoff

Because of our expertise in low fetal fraction analysis, we are able to provide results with high sensitivity and specificity, while maintaining a low test failure rate of 0.1%, without a fetal fraction cutoff[1].

Equity in care for every single patient in your practice[6].

Prequel with AMPLIFY technology provides a highly accurate result to ALL patients regardless of BMI, ethnicity, and race.



Individualized PPV/residual risk on all reports

ACMG[3] recommends including positive predictive value (PPV) and residual risk on every patient result. Prequel calculates a risk-adjusted PPV that factors in maternal and gestational age. This provides a personalized answer to a patient's key question of how likely it is that her pregnancy is affected so that you can confidently determine next steps for patient care.

COUNT ON IT. MYRIAD PREQUEL.

REFERENCES | MYRISK HEREDITARY CANCER

1. Mavaddat N, et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015 Apr 8;107(5). PubMed. 2. Michailidou K, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013 Apr;45(4): 353-61. 3. Michailidou K, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015 Apr;47(4):373-80. PubMed. 4. Tyrer J, et al. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004 23:1111-30. 5. Hughes E, et al. Development and validation of a combined residual risk score to predict breast cancer risk in unaffected women negative for mutations on a multi-gene hereditary cancer panel. Presented at SABCS 2017. 6. DeFrancesco et al. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting. Obstetrics & Gynecology 2018 - published online before print October 10, 2018. 7. Bellcross CA, et al. Genet Med. 2015;17(1):43–50. 8. Hartmann, L. C. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340, 77–84 (1999). 9. Rebbeck, T. R. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616–1622 (2002). 10. Plevritis, S et al. Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging. JAMA. 295(20), 2374–2384 (2006). 11. de Jong, A. E. et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130, 665–671 (2006). 12. ACOG Committee Opinion: Hereditary Cancer Syndromes and Risk Assessment, No. 793. December 2019. 13. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2019 Nov 12;322(7):652-665. 14. Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. V2.2021. 15. Judkins T. et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes BRCA1 and BRCA2 genes to assess hereditary cancer risk; BMC Cancer, 2014. 16. U.S. Food and Drug Administration, Center for Devices and Radiological Health (CDRH). BRACAnalysis CDxTM approval letter, December 19, 2014. Retrieved November 7, 2018, from http://www.accessdata.fda.gov/cdrh_docs/pdf14/P140020A.pdf. 17. Mersch J, et al. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing. JAMA - published online September 25, 2018. 18. Myriad internal data based on 103,990 myRisk tests reported between 01/03/2019 and 09/19/2019 ordered by OBGYN & Primary Care healthcare providers. 19. Gradishar W, et al. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. The Oncologist (2017). 20. Gradishar W, et al. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. The Oncologist (2017).

REFERENCES | FORESIGHT CARRIER SCREEN

1.Hogan GJ. et al. Clin Chem 2018; doi:10.1373/clinchem.2018.286823 2. Parker SE, et al. Birth Defects Res A Clin Mol Teratol. 2010;88(12):1008-1016 3.Johansen Taber KA et al., Genet Med 2018; https://doi.org/10.1038/s41436 018 0321 0 4.Kaseniit , K.E., Haque, I.S., Goldberg, J.D. et al. Genetic ancestry analysis on >93,000 individuals undergoing expanded carrier screening reveals limitations of ethnicity based medical guidelines. Genet Med (2020). https://doi.org/10.1038/s41436 020 0869 3 5.Beauchamp KA, et al. Genetics in Medicine 2017; doi:10.1038/gim.2017.69; Nimkarn S, et al. (Updated 2016 Feb 4). In: Adam MP, et al., editors.

REFERENCES | PREQUEL PRENATAL SCREEN

1. Hancock et al. (2019) Clinical experience across the fetal-fraction spectrum for a noninvasive prenatal screen with low test-failure rate. UOG. doi/pdf/10.1002/uog.21904. 2. Norton, M. et al Cell free DNA analysis for noninvasive examination of trisomy. The New England Journal of Medicine April 2015; 372: 1589-1597. 3. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin Summary, Number 226. Obstet Gynecol. 2020 Oct;136(4):859-867. 4. Gregg, A. R. et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet. Med. 18, 1056-1065 (2016). 5. Muzzey et al. (2019). Noninvasive prenatal screening for patients with high body mass index: Evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk. Prenatal Diagnosis. Doi/abs/10.1002/pd.5603. 6. Welker, N. C. et al. (2020) 'High-throughput fetal fraction amplification increases analytical performance of noninvasive prenatal screening', Genetics in medicine: official journal of the American College of Medical Genetics. doi: 10.1038/s41436-020-01009-5.

myriad® | WOMEN'S HEALTH

myriadwomenshealth.com | 180 Kimball Way, South San Francisco, CA 94080

myRisk Support | cscomments@myriad.com | (800) 469-7423

Foresight & Prequel Support | prenatalsupport@myriad.com | (888) 268-6795